Oppenheimer & Co. Inc. Trims Stake in TransMedics Group, Inc. $TMDX

Oppenheimer & Co. Inc. lessened its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 4.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 111,640 shares of the company’s stock after selling 5,730 shares during the quarter. Oppenheimer & Co. Inc. owned about 0.33% of TransMedics Group worth $12,526,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Geode Capital Management LLC lifted its position in shares of TransMedics Group by 1.4% in the second quarter. Geode Capital Management LLC now owns 804,650 shares of the company’s stock valued at $107,845,000 after acquiring an additional 11,241 shares in the last quarter. Marshall Wace LLP raised its stake in TransMedics Group by 258.7% in the 2nd quarter. Marshall Wace LLP now owns 546,787 shares of the company’s stock valued at $73,275,000 after purchasing an additional 394,340 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in TransMedics Group by 20.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock valued at $34,145,000 after purchasing an additional 86,721 shares in the last quarter. Zevenbergen Capital Investments LLC lifted its holdings in TransMedics Group by 112.7% in the 3rd quarter. Zevenbergen Capital Investments LLC now owns 258,523 shares of the company’s stock valued at $29,006,000 after purchasing an additional 136,995 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of TransMedics Group by 28.7% during the 3rd quarter. Principal Financial Group Inc. now owns 242,039 shares of the company’s stock worth $27,157,000 after purchasing an additional 53,995 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

TMDX has been the subject of a number of analyst reports. Morgan Stanley boosted their price objective on shares of TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 2nd. Jefferies Financial Group began coverage on shares of TransMedics Group in a research note on Monday, October 13th. They issued a “buy” rating and a $145.00 target price for the company. Wall Street Zen downgraded TransMedics Group from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. Needham & Company LLC raised their price objective on TransMedics Group from $148.00 to $166.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of TransMedics Group in a research report on Monday, December 22nd. Six investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $144.25.

TransMedics Group Stock Up 0.9%

Shares of NASDAQ TMDX opened at $136.34 on Tuesday. The stock has a market capitalization of $4.66 billion, a PE ratio of 55.20 and a beta of 2.06. The company has a quick ratio of 7.13, a current ratio of 7.69 and a debt-to-equity ratio of 1.43. The firm has a fifty day moving average of $132.84 and a 200-day moving average of $124.80. TransMedics Group, Inc. has a 52-week low of $62.07 and a 52-week high of $156.00.

Insider Activity at TransMedics Group

In other TransMedics Group news, Director David Weill sold 5,000 shares of the business’s stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $138.64, for a total transaction of $693,200.00. Following the completion of the sale, the director owned 12,134 shares of the company’s stock, valued at approximately $1,682,257.76. The trade was a 29.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Anil P. Ranganath sold 3,000 shares of the company’s stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $145.22, for a total value of $435,660.00. Following the sale, the insider owned 13,955 shares of the company’s stock, valued at $2,026,545.10. This represents a 17.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 8,920 shares of company stock worth $1,257,310. 7.00% of the stock is owned by insiders.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.